-
Distinguished group of scientific advisors to create the foremost
authority on mental health treatment in support of Genomind’s mission:
leveraging genetic testing and other scientific advances to improve
mental health outcomes -
Drs. Ruth Benca (University of California, Irvine), Kathleen Brady
(Medical University of South Carolina) and Naomi Simon (NYU School of
Medicine) join the team of esteemed mental health thought leaders on
Genomind’s Scientific Advisory Board
KING OF PRUSSIA, Pa.–(BUSINESS WIRE)–Genomind, a leader in genetics-based mental healthcare, today announced
that it has strengthened its leadership position in mental health
innovations by adding three thought leaders in psychiatry and neurology
to its Scientific Advisory Board (SAB):
-
Ruth Benca, MD, PhD, an expert on the connections
between sleep and brain health, is the Chair of Psychiatry and Human
Behavior at the University of California Irvine (UCI) -
Kathleen Brady, MD, PhD, a renowned addiction
specialist, who is the Vice President for Research at the Medical
University of South Carolina (MUSC) -
Naomi Simon, MD, MSc, a prominent authority in
complicated grief and posttraumatic stress disorders (PTSD), is a
Professor of Psychiatry at NYU School of Medicine, Vice Chair for
Research Faculty Development and Mentorship, and Director of the
Anxiety and Complicated Grief Program in the Department of Psychiatry
at NYU Langone Health
Drs. Benca, Brady, and Simon join a distinguished group of clinicians on
Genomind’s Scientific Advisory Board, all known for their work at
the forefront of psychiatric and neurologic research and clinical
practice. Additional board members include:
-
Maurizio Fava, MD, Massachusetts General Hospital, Harvard Medical
School -
Roy H. Perlis, MD, MSc, Massachusetts General Hospital, Harvard
Medical School - Stephen M. Stahl, MD, PhD, University of California, San Diego
-
Rudolph E. Tanzi, PhD, Massachusetts General Hospital, Harvard Medical
School - Scott T. Aaronson, MD, University of Maryland School of Medicine
-
Stephen V. Faraone, PhD, SUNY Upstate Medical University,
Massachusetts General Hospital, Harvard Medical School -
Anil Malhotra, MD, Albert Einstein College of Medicine, Zucker
Hillside Hospital, Feinstein Institute for Medical Research -
Mark A. Stein, Ph.D., ABPP, Seattle Children’s Hospital, University of
Washington
“We have been able to assemble a powerhouse of thought leadership on
mental health issues – among the best in the world – to support our goal
of advancing clinical innovations that evolve mental health,” said David
Krause, MD, FACP, Chief Medical Officer of Genomind Inc. “We are
honored to have Drs. Benca, Brady, and Simon, who share our sense of
urgency in expanding the tools available for improving outcomes for
mental health, join our advisory board. We look forward to working with
them and our other advisors to continue our important work in this
field.”
As members of Genomind’s Scientific Advisory Board, Drs. Benca, Brady,
and Simon will provide clinical and patient perspective to guide
development and utilization of Genomind’s innovative mental health
pharmacogenomics tests. In addition, they will add their particular
areas of expertise, alongside the other members of the Genomind SAB, to
steer Genomind’s future innovations in the mental health treatment
landscape.
Ruth Benca, MD, PhD
Dr. Ruth Benca is an internationally recognized authority on the
relationship between sleep and brain health, including neuropsychiatric
disorders. In addition to chairing the Department of Psychiatry and
Human Behavior at UCI, she has built a comprehensive sleep medicine
center focused on providing clinical care for sleep disorders and
developing a world-class translational research program. She has a broad
background in basic and clinical sleep research and has served as
principal or co-investigator on numerous projects funded by NIH and the
Department of Defense. She is the former Director of the Center for
Sleep Medicine at the University of Wisconsin, a past president of the
Sleep Research Society (SRS), former board member of the American
Academy of Sleep Medicine (AASM), and a Distinguished Life Fellow of the
American Psychiatric Association. Dr. Benca received her undergraduate
education at Harvard University and her MD degree and a PhD in Pathology
from the University of Chicago. She completed a residency in Psychiatry
and a fellowship in Sleep Medicine, also at the University of Chicago.
Kathleen Brady, MD, PhD
Dr. Kathleen Brady has been conducting scientific investigations and
clinical work in the field of addictions and psychiatric disorders for
over 30 years. Her research focuses on pharmacotherapy of substance use
disorders, comorbidity of psychiatric disorders and addictions, gender
differences and women’s issues in addictions, and the neurobiological
connections between stress and addictions. She has published over 300
peer-reviewed journal articles and co-edited 10 books. In addition to
her role as Vice President of Research at MUSC, she is the principal
Investigator of MUSC’s Clinical and Translational Science Award,
Principal Investigator of the Southern Consortium Node of the
NIDA-funded Clinical Trials Network and Director of MUSC’s Women’s
Research Center. She is also President of the International Society of
Addiction Medicine (ISAM). Dr. Brady received her bachelor’s degree from
Fordham University, a doctorate in pharmacology from the Medical College
of Virginia, and her medical degree with a residency in psychiatry from
MUSC.
Naomi M. Simon, MD, MSc
In addition to her roles at NYU Langone Health, Dr. Naomi Simon’s work
includes serving as a Senior Advisor to NYU’s Steven A. Cohen Military
Family Clinic. She has over 20 years of experience conducting clinical
and translational research in anxiety, depression, complicated grief and
stress related disorders. She is the former Director of the Center for
Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital
(MGH) and former Chief Medical Officer at Home Base. In this role, she
guided development of a novel clinical care model and the Home Base
Training Institute to address the unmet needs of returning veterans and
their families impacted by deployment related stress, PTSD, and
traumatic brain injury. Dr. Simon received an MD from Harvard Medical
School and completed a medical internship and residency in psychiatry at
Columbia Presbyterian Hospital/ New York State Psychiatric Institute.
She completed fellowship training in consultation psychiatry at MGH and
has a Masters in Epidemiology from the Harvard School of Public Health.
“Drs. Benca, Brady, and Simon bring key expertise in sleep, substance
abuse, and PTSD to our accomplished advisory team,” said Shawn
Patrick O’Brien, Chief Executive Officer, Genomind Inc. “As a
leading mental health care company, we are fortunate to have earned the
dedication of many renowned researchers and clinicians to support our
product development, and reaffirm our commitment to engage with clinical
innovators in psychiatric medicine to continue addressing patient needs.”
About Genomind
Genomind is a leading mental health care company, delivering the genetic
testing tools that empower clinicians to optimize treatment decisions
and create better outcomes for patients with mental illnesses. As the
scientific leader in genetic testing, Genomind offers the most
comprehensive mental health genetic test and services available.
Supported by a world-class genetics lab and unique consultative
approach, Genomind is advancing a new paradigm of personalized medicine
in mental health care. Learn more at www.genomind.com.
Contacts
Andrea Cohen
Sam Brown Inc
917-209-7163
[email protected]
Amy Pressman
Marketing Director, Genomind
267-532-8866
[email protected]
